Christopher Huff, MD
Interventional Cardiology · Columbus, OHNPI 1831366996
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $74,300 of the $119,422 with a category attached, or 62.2%. Inari Medical, Inc. accounts for 80.9% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2020 at $30,585 and has fallen 90.6% since, to $2,888 in 2025. Among interventional cardiology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $884.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$97K
- Inquis Medical, Inc.$8K
- Surmodics, Inc.$6K
- Boston Scientific$5K
- Silk Road Medical, Inc.$1K
- Medtronic$1K
- plus $2K from 13 others
Across 11 payments — averaging $1475.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$16K
What the payments were for
- Consulting fees$74,30062%
- Speaking & faculty fees$28,71324%
- Travel & lodging$11,87810%
- Food & beverage$4,5324%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 67 | $96,636 |
| Inquis Medical, Inc. | 3 | $7,775 |
| Surmodics, Inc. | 11 | $5,929 |
| Boston Scientific | 5 | $5,141 |
| Silk Road Medical, Inc. | 4 | $1,185 |
| Medtronic(2 entities) | 18 | $1,088 |
| Angiodynamics, Inc. | 4 | $336 |
| Endologix LLC | 2 | $276 |
| Penumbra, Inc. | 2 | $263 |
| Cardiovascular Systems Inc. | 3 | $180 |
| Abiomed | 1 | $149 |
| Abbott | 5 | $138 |
| W. L. Gore & Associates, Inc. | 1 | $136 |
| Stryker | 2 | $55 |
| Cook Medical LLC | 2 | $36 |
| Novo Nordisk | 2 | $35 |
| Edwards Lifesciences | 1 | $29 |
| Johnson & Johnson | 1 | $23 |
| Cardinal Health 200 LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CT THROMBECTOMY SYSTEM KIT$63,746
- FlowTriever$49,835
- ClotTriever$49,835
- FLOWTRIEVER CATHETER, S$28,946
- Aventus$7,642
- ReVene Thrombectomy Catheter$5,772
- GENERAL - THERAPIES$5,063
- ENROUTE Transcarotid Neuroprotection System$1,101
- ENROUTE Transcarotid Stent$1,101
- ClosureRFS$213
- AngioVac$184
- Diamondback Peripheral$173
- Diamondback Coronary$173
- ENDURANT IIS$167
- Penumbra System$153
- Impella$149
- GORE VIABAHN VBX Balloon Expandable Endo$136
- Torus Stent Graft System$129
- ENDOCROSS Device$129
- Resolute$117
How this compares
$119,422 in reported general payments places this provider in the 90th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 99 | $118,531 |
| XareltoRivaroxaban | 85 | $78,977 |
| ClopidogrelClopidogrel Bisulfate | 219 | $2,146 |
| Atorvastatin Calcium | 111 | $907 |
| Rosuvastatin Calcium | 60 | $907 |
| Cilostazol | 40 | $896 |
| Metoprolol Succinate | 59 | $650 |
| Ezetimibe | 30 | $463 |
| Losartan Potassium | 37 | $391 |
| Lisinopril | 28 | $352 |
| Carvedilol | 34 | $257 |
| Metoprolol Tartrate | 36 | $217 |
| Hydrochlorothiazide | 36 | $163 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 12 | $150 |
| Hydralazine Hcl | 14 | $132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $23 | $78,97785 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Columbus
- Gary AnselColumbus$3.3M
- John CheathamColumbus$1.4M
- Carlos Sanchez SotoColumbus$1.1M
- Steven YakubovColumbus$907K
- Mitchell SilverColumbus$562K
- John PhillipsColumbus$410K
- Michael JollyColumbus$281K
- Timothy SmithColumbus$149K
- Joseph CampbellColumbus$114K
- Aref AmroColumbus$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.